APRIGLIM MV2 TAB

Description

APRIGLIM MV2 Tablet is a prescription medication designed for the treatment of type 2 diabetes mellitus in adults, especially when blood glucose levels are inadequately controlled with dual therapy. It is a fixed-dose combination of three oral anti-diabetic agents:

• Glimepiride (2 mg): A sulfonylurea that increases insulin secretion from the pancreas.

• Metformin SR (500 mg): A biguanide that decreases hepatic glucose production and improves insulin sensitivity.

• Voglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the absorption of carbohydrates from the intestine, reducing postprandial blood glucose spikes.

This triple-action formulation provides a comprehensive approach to glycemic control by:

1. Enhancing insulin secretion (Glimepiride)

2. Improving insulin sensitivity and reducing liver glucose production (Metformin)

3. Controlling post-meal glucose spikes (Voglibose)

Indications:

• Type 2 diabetes mellitus not adequately managed by diet, exercise, and dual oral therapy

Benefits:

• Improved overall blood sugar control, including fasting and postprandial glucose

• Convenient once or twice daily dosing

• Targets multiple mechanisms of glucose regulation

Common Side Effects:

• Hypoglycemia (especially if meals are skipped)

• Gastrointestinal discomfort: bloating, flatulence, diarrhea

• Nausea, metallic taste, dizziness

Precautions:

• Not recommended in patients with type 1 diabetes or diabetic ketoacidosis

• Use cautiously in renal or hepatic impairment

• Monitor blood glucose and renal function regularly